Cav1.2 is the pore-forming subunit of L-type voltage-gated calcium channel (LTCC) that plays an important role in calcium overload and cell death in Alzheimer's disease.
| INTRODUC TI ON
Cav1.2 is the pore-forming subunit of L-type voltage-gated calcium channels (LTCC) and accounts for approximately 70% of LTCC in the brain (Zamponi, Striessnig, Koschak, & Dolphin, 2015) . Cav1.2 is mainly located at extra-and postsynaptic sites and plays a critical role in intracellular calcium transients (Tippens et al., 2008) . During aging, LTCC activity is increased, and calcium influx via LTCC may be the preferred source for calcium-induced calcium release (CICR), which plays a necessary role in aging-related biomarkers (Thibault, Gant, & Landfield, 2007) . Evidence has suggested that dysfunction of LTCC and calcium overload contribute to cell death and the pathophysiology of Alzheimer's disease (AD) (Bezprozvanny & Mattson, 2008) . Accordingly, LTCC inhibitors have exhibited therapeutic potential in AD (Nimmrich & Eckert, 2013) .
Estrogens are neuroprotective in brain aging and AD (EnglerChiurazzi, Brown, Povroznik, & Simpkins, 2016) . Estrogen deficiency promotes the generation of the toxic amyloid β protein (Aβ) (Yue et al., 2005) , supporting the role of estrogens in AD-like pathologies.
Among the multiple mechanisms underlying estrogen action in the brain (Nilsson et al., 2001) , the involvement of LTCC-mediated calcium dynamics has been documented (Vega-Vela et al., 2016) . Brief exposure (90 s) of 17β-estradiol (E2) induces rapid increase in LTCC currents, which is mediated by direct interaction of E2 with LTCC subunit (Sarkar et al., 2008) . Interestingly, estrogen also induces rapid release of calcium from intracellular store within minutes in isolated neurons, possibly by mechanism of CICR (Beyer & Raab, 1998; Thibault et al., 2007) . On the other hand, long-term estrogens can inhibit LTCC in neuronal cells. For instance, E2 (25 hr) inhibits the high-voltage-activated calcium channel currents, which are associated with LTCC (Kumar & Foster, 2002) . In glutamate-or high potassium-primed neurons, E2 (5 min ~ 25 hr) reduces calcium entry and cell death through LTCC (Kurata, Takebayashi, Kagaya, Morinobu, & Yamawaki, 2001; Sribnick, Re, Ray, Woodward, & Banik, 2009) . Chronic E2 replacement prevents the age-related increase of LTCC currents in the hippocampus of ovariectomized (OVX) rats (Brewer et al., 2009) . Therefore, identifying the molecular mechanisms underlying estrogen regulation of Cav1.2 may aid to the understanding and treatment of AD.
In the current study, we found that E2 reduced Cav1.2 protein through estrogen receptor α (ERα). This effect involved lysine 29-linked ubiquitin chains and the E3 ligase Mdm2 (double minute 2 protein). In OVX APP/PS1 mice, systematic administration of E2 and ERα agonist PPT (propylpyrazoletriol) led to the reduced Cav1.2 protein and the enhanced Cav1.2 ubiquitination in the brain, which were accompanied by the improved cognitive functions.
| RE SULTS

| Estrogen reduced Cav1.2 protein through ERα in primary neurons
As shown in Figure 1a and b, 17β-estradiol (E2) significantly reduced Cav1.2 expression at concentrations ranging from 10 nM to 1 μM.
Cav1.2 protein level was decreased at 6 hr and remained to be decreased for up to 48 hr in primary neurons incubated with E2. This effect seemed to be dependent on estrogen receptors (ERs), as a nonselective ER antagonist fulvestrant (ICI182780, ICI, 1 μM) diminished the effect of E2 on Cav1.2 ( Figure 1c) . Similar results were found by immunofluorescent studies (Figure 1d ). To further assess whether E2 may affect Cav1.2 function, the voltage-gated calcium currents (I Ca 2+ density) were measured using whole-cell patch recordings. As shown in Figure 1e , the peak I Ca 2+ density (pA/pF) was significantly decreased by E2 treatment (24 hr), whereas ICI attenuated this effect. These results indicated that E2 reduced Cav1.2 protein in cultured primary cortical neurons, which was mediated by ERs.
To identify which ER subtype(s) might mediate E2 effect on
Cav1.2, we tested the effect of the selective ERα agonist (PPT, 10 nM) or ERβ agonist (diarylprepionitrile, DPN, 10 nM) on Cav1.2 incubated in cortical neurons for 24 hr. As shown in Figure 1f , PPT but not DPN alone significantly reduced Cav1.2 expression.
Combined incubation with PPT and DPN had no additive effect, compared with PPT alone. Consistently, PPT but not DPN significantly reduced I Ca 2+ density (Figure 1g ). The involvement of ER subtype was further assessed using lentivirus bearing ERα or ERβ
shRNA. Primary screening with three different sequences targeting
ERα or ERβ mRNA showed that ERα shRNA2 and ERβ shRNA3 were most effective in reducing ERα or ERβ protein, respectively ( Figure   S1 ). As expected, ERα shRNA2 significantly increased Cav1.2, which attenuated E2-induced reduction of Cav1.2 ( Figure 1h ). In contrast,
ERβ shRNA3 did not alter the basal Cav1.2 and failed to further attenuate Cav1.2 reduction by E2 (Figure 1i ). These results indicated that ERα mediated E2 reduction of Cav1.2.
| ERα regulation of Cav1.2 involved K29-linked ubiquitin chains
Cav1.2 protein can be regulated at multiple levels (Dai, Hall, & Hell, 2009) . It was unlikely that ERα may affect Cav1.2 at transcriptional level, as Cav1.2 mRNA was not changed ( Figure S2A and B).
Moreover, ERα agonist PPT also failed to alter Cav1.2 phosphorylation. And the level of the calcineurin (PP2B, CN), the phosphatase involved in Cav1.2 dephosphorylation (Oliveria, Dell'Acqua, & Sather, 2007) , was not altered (Figure S2C and D) . Although PPT enhanced CN association with Cav1.2, CN inhibitor FK506 did not prevent PPT effect on Cav1.2 in primary neurons ( Figure S2E and F). Thus, it was also unlikely that the phosphorylation-related mechanisms are involved in ERα-mediated Cav1.2 reduction.
It is reported that ubiquitin-proteasome system (UPS) controls Cav1.2 degradation (Altier et al., 2011) . Thus, we compared the effect of the proteasomal inhibitor MG132 (10 μM for 24 hr) and the lysosomal inhibitor chloroquine (CQ, 50 μM for 24 hr) in primary neurons. As shown in Figure 2a and b, MG132 significantly increased Cav1.2 under basal condition and diminished PPT-induced reduction of Cav1.2, whereas CQ was without effect. Accordingly, the naturally occurred Cav1.2 fragments in primary neurons (Michailidis et F I G U R E 1 Estrogen decreases Cav1.2 protein through ERα in primary cortical neurons. (a) Representative Western blots (top) and quantification (bottom) of Cav1.2 in primary cortical neurons in the absence (Ctl) and presence of estrogen at 10, 100 nM, and 1 μM, respectively; n = 4. (b) Representative Western blots (top) and quantification (bottom) of Cav1.2 in cortical neurons incubated with estrogen (100 nM) at different times; n = 3. (c) Representative Western blots (top) and quantification (bottom) of Cav1.2 in cortical neurons treated with DMSO (Ctl), the ER antagonist ICI182780 (1 μM, ICI), estrogen (100 nM, E2), and E2 with ICI, respectively n = 4. (d) Representative immunofluorescent images of Cav1.2 (green) relative to neuronal marker MAP2 (red), in cortical neurons treated with DMSO (Ctl), ICI, E2, and E2 with ICI for 24 hr (n = 3). Scale bar, 10 μm. (e) I-V plots (top) and quantifications (bottom) of calcium mediated current (ICa 2+ ) density (pA/pF) in primary cortical neurons treated with DMSO (Ctl, n = 15), ICI (n = 9), E2 (n = 9), and E2 with ICI (n = 11) for 24 hr. (f) Representative Western blots (top) and quantification (bottom) of Cav1.2 in primary cortical neurons treated with ERα agonist PPT (10 nM), ERβ agonist DPN (10 nM), and PPT with DPN for 24 hr; n = 6. (g) I-V plots (top) and quantifications (bottom) of ICa 2+ density (pA/pF) in cortical neurons treated with DMSO (Ctl, n = 15), PPT (n = 9), DPN (n = 9), and PPT with DPN (n = 11). (h) Representative Western blots (top) and quantification (bottom) of Cav1.2 in cortical neurons in the absence (Ctl) and presence of mock shRNA, mock shRNA with estrogen (E2, 100 nM), ERα shRNA2, and ERα shRNA2 with E2, respectively (n = 4). (i) Representative Western blots (top) and quantification (bottom) of Cav1.2 in cortical neurons in the absence (Ctl) and presence of mock shRNA, mock shRNA with estrogen (E2, 100 nM), ERβ shRNA3, and ERβ shRNA3 with E2, respectively (n = 3). *p＜0.05,**p＜0.01,***p＜0.001 (ANOVA) al., 2014) were all decreased by PPT (Figure 2c ). Further co-immunoprecipitation experiments showed that Cav1.2 ubiquitination was significantly increased by PPT (Figure 2d ). These results suggested that UPS played a role in ERα regulation of Cav1.2.
Ubiquitin (UB) protein contains seven lysine (K) residues at positions 6, 11, 27, 29, 33, 48, and 63, respectively . In addition, poly-UB chain assembly can occur at any of these lysine residues (Pickart & Fushman, 2004 K29-linked UB chains can be specifically regulated by the deubiquitinating enzyme TRABID (TRAF-binding protein domain) (Kristariyanto et al., 2015) and TRABID mutant C443A that binds to but does not hydrolyze K29-linked UB chains (Kristariyanto et al., 2015) . As shown in Figure 2i , in TRABID-transfected cells, PPTinduced reduction of Cav1.2 was diminished. In contrast, C443A
overexpression did not significantly affect PPT-induced reduction of Cav1.2. Together, these results indicated that K29-linked UB chains were critical in mediating ERα-induced ubiquitination and degradation of Cav1.2 in neuronal cells.
| The E3 ligases Mdm2 and the pest sequence in Cav1.2 were Involved in ERα regulation of Cav1.2
The E3 ligases Mdm2 (double minute 2 protein) and CHIP (STIP1 homology and U-Box-containing protein 1, STUB1) are reportedly associated with ERα signaling (Fan, Park, & Nephew, 2005; Liu, Schwartz, & Brooks, 2000) . To test whether Cav1.2 might interact with these E3 ligases, we first assessed Cav1.2 association with Mdm2, CHIP, and Derlin-1; the latter has no known associa- It is reported that a PEST motif is involved in Mdm2-mediated degradation of PSD95 (postsynaptic density 95) (Colledge et al., 2003) . Interestingly, two PEST sequences (PEST1/3) have been found in Cav1.2 (Michailidis et al., 2014) . Thus, we assessed the effect of membrane-permeable synthetic PEST1/3 peptides on ERα regulation of Cav1.2 ( Figure 3e ). Effective intracellular localization of these peptides and Cav1.2 enhancement were proved by fluorescent and Western blotting analyses ( Figure S3 ). As shown in To further verify that Mdm2 affected Cav1.2 protein and ubiquitination in vivo, we introduced Mdm2 constructs into fetal brain using the in utero electroporation technique and assessed cortical neuronal Cav1.2 protein and its ubiquitination after birth by using immunofluorescent analysis. We found that in Mdm2-overexpressing neurons (Figure 4a ), the intensity of Cav1.2 was significantly decreased (Figure 4b ), whereas the colocalization of ubiquitin and Cav1.2 was significantly increased, as measured by ubiquitin 
| PPT treatment reduced Cav1.2 protein in OVX APP/PS1 mice
As shown in Figure 5a These results indicated that ERα activation promoted the ubiquitination and degradation of Cav1.2 in OVX APP/PS1 mice.
| PPT treatment attenuated cognitive decline in APP/PS1 mice
We next assessed the effect of E2 or ER agonists on spatial and associative learning and memory performances in OVX APP/PS1 mice.
In the hidden platform test, the escape latency and total traveling distance in E2-or PPT-treated OVX APP/PS1 (AD + E2 or AD + PPT) mice were significantly shorter than that in saline-treated OVX APP/ PS1 (AD) mice beginning on the third day (Figure 6a-c) . In the probe trial when the platform was removed, the passing times crossing over 
| D ISCUSS I ON
The efficacy of estrogen-based hormone therapy (HT) in AD is not conclusive. Some studies reveal that HT may reduce the risk of AD in postmenopausal women (Zandi et al., 2002) , whereas others find that HT does not reduce dementia or even has an adverse effect (Shumaker et al., 2004) . One explanation is that compared with the natural E2, the conjugated equine estrogen used in clinics does not easily diffuse into the brain (Lan, Zhao, & Li, 2015; Steingold, Cefalu, Pardridge, Judd, & Chaudhuri, 1986) . Another explanation is that the initiation of the therapy may have been delayed (Sherwin, 2005) . Given that LTCC blockers attenuate AD-associated pathology, E2-induced reduction of Cav1.2 in our study favors the beneficial role in AD.
Evidence has suggested that UPS is involved in Cav1.2 degradation. For instance, the ubiquitin ligase RFP2 (Ret finger protein 2) mediates proteasomal degradation of Cav1.2 in neuronal cells (Altier et al., 2011) . Cav1.2 degradation is promoted by ubiquitin ligase NEDD4-1 (neuronal precursor cell-expressed developmentally down-regulated 4-1) and is inhibited by deubiquitinase USP2-45 (ubiquitin-specific protease 2-45) in kidney cells (Rougier, Albesa, Abriel, & Viard, 2011; Rougier et al., 2015) . The calcium-dependent cleavage of Cav1.2 fragment channels through UPS increases with aging, which can be blocked by LTCC inhibitor in vivo (Michailidis et al., 2014) . Consistently, proteasomal inhibitor MG132 prevents Cav1.2 degradation by ERα (Figure 2 ), suggesting that ERα may use UPS to monitor Cav1.2 degradation. The seven lysine residues in UB play distinct roles in cellular function (Swatek & Komander, 2016) . While K29-linked chains and K29-specific deubiquitinating enzyme TRABID are involved in proteasome regulation (Kim et al., 2011; Kristariyanto et al., 2015) , K6-linked UB chains are associated with mitophagy but with no known functions in UPS (Swatek & Komander, 2016 (Figure 2g) , suggesting that the poly-UB chains containing K6 and K29 are important in Cav1.2 degradation. In line with this, in cells transfected with UB mutants other than K6/ K29 including K11, K27, K33, K48, and K63, when both K6 and K29 were among those being mutated, the increase of Cav1.2 occurs in control condition (Figure 2e ). Interestingly, only K29 seems to be critical in ERα regulation of Cav1.2, as PPT-induced reduction of Cav1.2 is diminished only in K29R but not in K6R-overexpressing cells. In line with this, the deubiquitinating enzyme TRABID that selectively acts on K29 in mammalian cells also diminishes PPT effect (Figure 2i ).
ERα is known to physically interact with Mdm2 (Liu et al., 2000) , which mediates ubiquitination through K11-, K29-, and K63-linked UB polymers (Wu & Leng, 2015) . In addition, the conserved PEST motif is involved in Mdm2-mediated target protein degradation (Colledge et al., 2003) . It has been reported that similar PEST sequences are located in Cav1.2, which provides signaling for UPS in calcium-induced mid-channel proteolysis and Akt-induced Cav1.2 degradation (Catalucci et al., 2009; Michailidis et al., 2014 (d) The synthesized PEST sequences, which is known to play a role in Mdm2-associated protein degradation (Colledge et al., 2003) , attenuate PPT-induced reduction of Cav1.2 (Figure 3f ).
In physiological conditions, both ERα and ERβ seem to be involved in spatial memory enhancement (Walf, Paris, & Frye, 2009 ).
ERα agonist PPT or ERβ agonist DPN improves cognitive function
in OVX mice and rats (Boulware, Heisler, & Frick, 2013; Hammond, Mauk, Ninaci, Nelson, & Gibbs, 2009 ). In AD however, only ERα shows beneficial role (Lan et al., 2015) . PPT but not DPN rescues cognitive decline and Aβ deposition in another AD model 3xTg-AD mice (Carroll & Pike, 2008) . This inconsistency may be associated with different neuroprotective effects of PPT and DPN in pathological conditions. While PPT prevents Aβ-induced neuronal death in hippocampal neurons (Merlo, Spampinato, Capani, & Sortino, 2016) , DPN is modestly protective (Thibault et al., 2007) . In our study, PPT- 
| E XPERIMENTAL PROCEDURE S
| Antibodies and reagents
Antibodies against Cav1.2 (ab84814 and ACC-003) were from Abcam (Cambridge, UK) and Alomone, respectively, which produced identical Western blots. Those against β-actin (ab6276), MAP-2 (ab32454), ERα (ab3573), ERβ (ab104804), calcineurin (ab3673), Mdm2 (ab16895), and ubiquitin (ab19247) were purchased from Abcam. pSer1928-Cav1.2 (A010-70) was from Badrilla (United Kingdom). 17β-estradiol (E2758), propylpyrazoletriol (PPT,
(C2211), ammonium chloride (A0171), chloroquine (C6628), carfilzomib (791938), and other reagents were purchased from Sigma (St. Louis, MO, USA). Lipid solvents were made in stock solutions in DMSO (1:1,000 ~ 2,000).
| Gene constructs
pCMV6-Myc-Mdm2 and pCMV6-Myc-p14ARF were purchased from OriGene (USA). TRABID (DU# 49067) and TRABID mutant C443A (DU# 49089) were purchased from MRC PPU Reagents and Services (University of Dundee). pRK5-HA-ubiquitin was obtained from Addgene. All ubiquitin mutants were made from pRK5-HA-ubiquitin plasmid by mutagenesis. pRK5-HA-Ubiquitin-K0 (no lysine), pRK5-HA-Ubiquitin-K6 (keep lysine at position 6), pRK5-HA-Ubiquitin-K11, pRK5-HA-Ubiquitin-K27, pRK5-HAUbiquitin-K29, pRK5-HA-Ubiquitin-K33, pRK5-HA-Ubiquitin-K48, pRK5-HA-Ubiquitin-K63, pRK5-HA-Ubiquitin-K6R (keep all lysine residues except lysine at position 6 mutated to arginine), pRK5-HA-Ubiquitin-K29R, pRK5-HA-Ubiquitin-K63R, CHIP with myc tag, and Derlin-1 with HA tag were cloned to pcDNA3, respectively.
| Primary culture of cortical neurons
Cortical neurons were extracted from prenatal pups on embryonic day 18. Cells were placed on poly-L-lysine (0.1 mg/ml)-coated 6-well plates, at a density of 2 × 10 6 cells/ml for biochemical experiments and 0.5 × 10 6 cells/ml for molecular and immunohistochemistry experiments. Cultures were maintained in serum-free neurobasal (NB) medium (2% B27, 2 mM glutamine, 1% penicillin/streptomycin; Invitrogen) at 37°C with 5% CO 2 . Fifty percent of the medium was exchanged with fresh medium every other day for 2 weeks. On the day before experiment, culture medium was completely replaced by fresh medium in the presence of accurate dilution of chemicals. 
| Cell culture and gene transfection
| Western blotting and co-immunoprecipitation
Western blotting of Cav1.2 was performed as previously described (He et al., 2016) . Blots were visualized with chemiluminescence detection reagent kit (Millipore, 345818) 
| Immunofluorescence
Brain sections were washed with ice-cold PBS, then fixed in icecold 4% paraformaldehyde for 10 min, permeabilized in 0.1% Triton X-100 for 10 min, and blocked with 10% normal goat serum for 1 hr at 37°C with extensive PBS washings between each step. Specimens were incubated with appropriate primary antibodies (1:50 in PBS) at 4°C overnight. The sections were then washed 6 × 2 min with PBS, followed by incubation with the secondary antibody Alexa 549 or Fluro 488 (1:100 in PBS) at 37°C for 1 hr. After sealing with a mixture of glycerol and PBS at a ratio of 1:1, the immunofluorescent-labeled sections were examined using a laser scanning confocal microscope (Nikon, Japan) with an Olympus IX 70 inverted microscope (Olympus, Tokyo, Japan) equipped with a Fluoview FVX confocal scan head.
| Whole-cell patch-clamp recording
Voltage-dependent calcium-mediated currents (ICa   2+   ) were recorded from cultured cortical neurons from 7 to 11 days in vitro (DIV), at room temperature using a MultiClamp 700B amplifier (Axon Instruments).
The recording chamber was perfused with Tyrode's solution con- sists of 300-700 ms to −30 mV followed by 50 ms to −50 mV, before each test pulse was used to inactivate T-type Ca 2+ channels and Na+ channels. ICa 2+ was elicited by 300 ms test pulses of variable amplitude (−40 to +60 mV at a step of 10 mV) from a holding potential of −60 mV. The interval between test pulses was 10 s.
| Quantitative RT-PCR
RT-PCRs were performed on a Bio-Rad IQ5 detection system (Bio-Rad, Hercules, CA, USA). The primer sequences for Cav1.2 were as follows: 5′-TACCGTCAGTTCCACACAGC-3′ and 5′-CTTCAGAGTCAGGCAGAGCA-3′. The threshold cycle (Ct) value of each sample was calculated, and the relative mRNA level was normalized to the GAPDH mRNA value.
| Lentivirus infection
The target shRNAs against rat ERα/β gene (NM_012689/NM_012754)
were designed as follows: ERα-1: GATAAGAACCGGAGGAAGA, ERα-2:
CCAGAATGGCCGAGAGAGA, and ERα-3: GTAAATGTGTAGAAGG CAT; ERβ-1: TGAGCAAAGCCAAGAGAAA, ERβ-2: TCACTAAGCTGGC GGACAA, and ERβ-3: CCAAATGTGCTATGGCCAA. Negative control was the scrambled sequence with no homology to rat genes. The recombinant lentiviral vector bearing rat ERα/β shRNAs was produced by Shanghai GeneChem Co., Ltd. (Shanghai, China). At 10 DIV, ER-related lentivirus was added to the culture for 72 hr according to the manufacturers' instruction (GeneChem, Shanghai, China), while transfection of Mdm2 was performed in HT22 cells.
| In utero electroporation and related immunofluorescence
Briefly, in utero electroporation was performed on pregnant C57/ B6L mice on embryonic day 14.5 (E14.5) as previously described (Saito, 2006) . The vector and Mdm2 plasmids were mixed with the Venus-GFP with a ratio of 3:1 at a final concentration of 1,000 ng/ μl. The mixture was injected into lateral ventricle. The electrode (CUY650P5, NEPA GENE) was positioned flanking the ventricular zones with the anode on the target side, and the embryos were then pulsed with a super electroporator NEPA21 type II (NEPA GENE) according to the following procedure: voltage = 33 V, pulse length = 50 ms, pulse interval = 950 ms, pulse number = 3.
The uterus was then returned to the abdominal cavity for further development. After birth, the brains were perfused with PBS on P0 and were fixed in 4% PFA (Sigma) overnight at 4°C, and then were replaced with 20% sucrose for 8 hr, followed by 30% sucrose at 4°C for an additional 8 hr. The brains were cut into coronal slices using a cryostat microtome (CM1950, Leica) and subjected to immunofluorescence staining. Slices were permeabilized and blocked in 10% goat serum, 3% BSA, and 0.3% Triton X-100 in PBS. Brain sections were then incubated with primary antibody (Cav1.2 1:100, Ubiquitin 1:100) for 1 hr at 37°C and then with the fluorescent-conjugated secondary antibodies (goat anti-mouse Alexa 647 1:100, goat anti-rabbit Cy3 1:100) for 1 hr at 37°C.
Confocal images were acquired and analyzed with the ZEISS system (LSM800). All animal studies were approved by the animal care committee of Chongqing Medical University. Image assay was performed using ImagePro Plus 6.0.
| Peptides synthesis and treatment
Peptide sequences that were designed to mimic the PEST1 (S446/459) and PEST3 (S840/861) were synthesized and purified by Pepmic Co. Ltd (Suzhou, China). The sequences were as follows: YGRKKRRQRRR-DIDPENEDEGMDED-GFP for TAT-PEST1, YGRKKRRQRRR-DIDKENEDEGKDED-GFP (ΔPEST1) for scrambled, YGRKKRRQRRR-HSNPNTAGEEDEEEPEMPVGPR-GFP for TAT-PEST3, and YGRKKRRQRRR-HSNPNPAGEEDKEEPAMPVGPR-GFP (ΔPEST3) for scrabbled control (Yu, Wu, Liu, Ge, & Wang, 2008) . They were all directly diluted in serum-free neurobasal (NB) medium before use. At 9 DIV, primary neurons were washed once and maintained in antibiotic-free NB medium overnight. Cells were subsequently treated with 0, 5, 100, or 150ìM PEST peptides for 0, 2, 6, and 12 hr at 37°C with 5% CO2, respectively.
| Animal treatment
Wild-type and APPswe/PS1E9 transgenic mice (APP/PS1) were obtained from Nanjing University (China). Eight-month-old female APP/PS1 mice were bilaterally ovariectomized (OVX) for 14 days.
Animals were subcutaneously injected daily with vehicle, 17β-estradiol (E2, 30 μg/kg), PPT (1 mg/kg), and DPN (1 mg/kg) for two weeks. The dosage of E2 is thought to be within physiological range;
and those of PPT and DPN are functional (Avtanski et al., 2014) .
| Morris water maze and contextual and cued fear conditioning
The Morris water maze test included four platform trials per day for five consecutive days and a probe trial on the sixth day. Swimming activities (latency, distance, and strategy of search) were recorded by a video and analyzed by image analyzing software (ANY-maze; Stoelting). For contextual and cued fear conditioning, mice were tested in a 3-day paradigm. Behavior was recorded by video camera, and freezing data were measured using FreezeScan software.
| Statistical analyses
Data were presented as means ± SEM from at least three independent experiments. The statistical comparisons between two groups were tested using Student's t test. The comparisons among groups were tested using one-way or two-way ANOVA, and a post hoc pairwise comparison was used where it applied.
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